A 38-year-old woman with newly diagnosed T2DM developed euglycemic diabetic ketoacidosis after starting semaglutide and, a week later, metformin and the SGLT2 inhibitor enavogliflozin, while fasting.
In plain wordsOne woman developed a serious blood acid problem after starting semaglutide with an SGLT2 inhibitor; one case cannot show the cause.
- Peptide
- Semaglutide
- Outcome
- Not applicableEuglycemic diabetic ketoacidosis
- Study
n = 1
- Outcome group
- Adverse events · Metabolic and weight
Measurements
- Glucose
- 137 mg/dL
- at presentation
- HbA1c
- 9.3%
- at presentation
Source sentences
Laboratory results showed a glucose level of 137 mg/dL, urine ketones (+++), lactate level of 4.87 mg/dL, HbA1c of 9.3%, C-peptide of 0.88 ng/mL, and high anion gap metabolic acidosis.
3 context sentences(design, population, supporting numbers)
She had recently initiated semaglutide (GLP-1RA) for weight loss and practiced prolonged intermittent fasting.
One week prior, she had started metformin and enavogliflozin, a selective SGLT2 inhibitor.
She was diagnosed with euDKA and treated with IV fluids, insulin infusion, dextrose, and potassium supplementation.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.